Role of clinical biomarkers in predicting the effectiveness of omalizumab.

Qing ZhangChunxiao LiJingxuan WanMengyuan ZhangYing NongJiang-Tao Lin

Published in: Therapeutic advances in respiratory disease (2023)

The responsiveness of omalizumab is not associated with pretreatment clinical biomarkers, and these biomarkers should not be used to predict the responsiveness of omalizumab.

Keyphrases

randomized controlled trial